Navigation Links
Therapure Biopharma Inc. has Acquired Plasma Protein Purification Technology From Upfront Chromatography A/S
Date:12/2/2013

Mississauga, ON (PRWEB) December 03, 2013

Therapure Biopharma Inc. and Upfront Chromatography A/S have announced today that they have entered into an agreement for Therapure to acquire the assets and associated business related to human plasma fractionation from Upfront.

Upfront has developed over the last 15 years, a proprietary protein purification technology, based on Expanded Bed Adsorption (EBA) chromatography which offers significant advantages over other purification technologies.

As a result of the acquisition, Therapure gains exclusive rights for the commercialization of the Upfront technology relevant to the human plasma fractionation field. Therapure will continue to develop and market this technology under the new trademark PlasmaCap EBA.

Nick Green, CEO of Therapure, commented: “The acquisition of the PlasmaCap EBA technology is an important addition to Therapure’s purification portfolio. With PlasmaCap EBA, Therapure now possesses a technology to capture therapeutic plasma proteins that is highly efficient and less damaging to the end product compared to conventional methods of fractionation. Ultimately PlasmaCap EBA allows for a more cost-effective process to manufacture plasma proteins. Therapure has established an excellent reputation as a biologics contract development and manufacturing organization (CDMO) with integrated services including plasma protein purification. The acquisition of this technology will further support Therapure’s reputation as a leader in the biologics manufacturing sector in general, and as a global leader in terms of plasma protein purification. We feel strongly that this technology can add significant value to our clients as they seek to optimize their manufacturing processes and associated economics.”

Upfront divested their pharmaceutical business unit in April 2010 to DSM Biologics, and is now focusing on their BioMine business line, where the technology is offered to the food/feed ingredients business for extraction of food grade proteins.

“We see this additional divestment of our technology to Therapure as a major milestone for Upfront,” commented Michael Pålsson, CEO of Upfront. “It is yet another significant blue-stamp of our technology, driven by its value creation in the capture of high value proteins. We are now ready to focus 100% on our BioMine business which aims to valorize under-utilized side and waste streams from the food, feed and biofuel industries. There is a broad range of food and feed industries in the world with large volumes of side and waste streams containing valuable proteins. We are able to help these manufacturers get more value out of these streams, and at the same time we see a growing, global need for alternative protein sources to feed the world’s population.”

About PlasmaCap EBA
PlasmaCap EBA is an innovative technology for cost-effective capture of plasma proteins at high yields and purities. PlasmaCap EBA uses proprietary high density resins in expanded bed adsorption (EBA) chromatography to capture plasma proteins directly from plasma or fractionated plasma materials. Through substantial development efforts, PlasmaCap EBA has been able to achieve significant capture yields for major plasma proteins of value. PlasmaCap EBA is owned by Therapure Biopharma Inc., which has developed the technology to enhance its contract manufacturing offerings for plasma fractionators, plasma protein manufacturers, and biopharma manufacturers.

Visit http://www.plasmacap.com for more information.

About Therapure Biopharma Inc.
Therapure Biopharma Inc. is an integrated biopharmaceutical company focused on complex biological therapeutics and technologies that can provide new options for patient care. It is comprised of Therapure Biomanufacturing, the award-winning CDMO division and Therapure Innovations, the proprietary drug pipeline and platform technology research and development division. Therapure Biopharma Inc.'s 130,000 sq. ft. cGMP facility includes biomanufacturing, research and quality-control laboratories and is built to meet FDA (USA), HPFB (Canada), EMA (Europe) and MHRA (UK) standards.

Visit http://www.therapurebio.com for more information.

About Upfront Chromatography
Upfront Chromatography A/S is a Danish high-tech company located in Copenhagen. Upfront Chromatography offers industrial-scale customized separation solutions to isolate and purify soluble proteins from industrial process streams.

Visit http://www.upfront-dk.com for more information.

For more information, please contact:

Nicholas Green
President and CEO
Therapure Biopharma Inc.
Tel: +1 (905) 286 6200
plasmacap(at)therapurebio(dot)com

Michael Pålsson
CEO
Upfront Chromatography A/S
Tel: +45 60 82 92 00
sales(at)upfront-dk(dot)com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11190204.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
11. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
Breaking Biology News(10 mins):